At the news
? NEUTRALIMPACT 5/10 PRESS-RELEASE filed Feb 27, 2026 at 08:30 ET
CG Oncology reported financial results for Q4 and full year 2025, highlighting a cash position of $742.2 million as of December 31, 2025, with an increase to $903.0 million by February 26, 2026, due to ATM share sales. The company expects this cash to fund operations into the first half of 2029. Key upcoming catalysts include topline Phase 3 data from the PIVOT-006 trial in intermediate-risk NMIBC and Phase 2 combination data from CORE-008 Cohort CX, both expected in the first half of 2026.
- Cash, cash equivalents, and marketable securities were $742.2 million as of December 31, 2025, and increased to $903.0 million by February 26, 2026.
- Net loss attributable to common stockholders was $161.0 million for full year 2025, up from $88.0 million in 2024.
- R&D expenses increased to $116.6 million in 2025 from $82.1 million in 2024; G&A rose to $73.5 million from $33.7 million.
- Topline Phase 3 data from PIVOT-006 trial in intermediate-risk NMIBC expected in 1H 2026.
Before · The news · First close · A day later · A week later
Replay the market's reaction
Step through every 5 minutes around the news, then see how it compares with similar events.
Subscribe for Full Access